<DOC>
	<DOCNO>NCT00400153</DOCNO>
	<brief_summary>The primary objective study compare effect ipratropium bromide/salbutamol inhalation spray combination administer Respimat® inhaler ( 20 mcg/100 mcg ) , ipratropium bromide inhalation spray administer Respimat® inhaler ( 20 mcg ) , COMBIVENT® MDI administer q.i.d FEV1 interval treatment period 12 week patient COPD . Specifically , non-inferiority Combivent Respimat® COMBIVENT® MDI FEV1 AUC 0 6 hour , superiority Combivent Respimat® Atrovent Respimat® monotherapy FEV1 AUC 0 4 hour , non-inferiority Combivent Respimat® Atrovent Respimat® monotherapy FEV1 AUC 4 6 hour analyze . In addition , steady state pharmacokinetics one dose interval follow 4 week therapy characterize subgroup patient .</brief_summary>
	<brief_title>Respimat® Combivent Trial Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Outpatients either sex , 40 year old , diagnosis COPD ( FEV1 65 % predict normal FEV1/FVC 70 % ) . Patients significant disease COPD may either put patient risk participation study disease may influence result study patient 's ability participate study , history asthma allergic rhinitis , regularly use daytime oxygen therapy 1 hour per day investigator 's opinion unable abstain use oxygen therapy use oral corticosteroid dication unstable dos ( i.e. , less 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day exclude .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>